Azitra, Inc. (AZTR)

NYSEAMERICAN: AZTR · IEX Real-Time Price · USD
0.203
+0.002 (1.15%)
At close: Mar 28, 2024, 3:36 PM
0.201
-0.002 (-1.08%)
After-hours: Mar 28, 2024, 5:38 PM EDT

Company Description

Azitra, Inc., a pre-clinical biopharmaceutical company, focuses on developing therapies for precision dermatology using engineered proteins and live biotherapeutic products to treat skin diseases.

It is developing ATR-12, a genetically modified strain of S. epidermidis for treating Netherton syndrome, a skin disease; ATR-04, a genetically modified strain of S.

epidermidis for treating the papulopustular rash experienced by cancer patients undergoing epidermal growth factor receptor inhibitor; and ATR-01, an engineered recombinant human filaggrin protein for treating ichthyosis vulgaris, a skin disease.

The company was incorporated in 2014 and is based in Branford, Connecticut.

Azitra, Inc.
Azitra logo
Country United States
Founded 2014
IPO Date Jun 16, 2023
Industry Biotechnology
Sector Healthcare
Employees 10
CEO Francisco D. Salva

Contact Details

Address:
21 Business Park Drive, Suite 6
Branford, Connecticut 06405
United States
Phone (203) 489-0183
Website azitrainc.com

Stock Details

Ticker Symbol AZTR
Exchange NYSEAMERICAN
Fiscal Year January - December
Reporting Currency USD
IPO Price $5.00
CIK Code 0001701478
ISIN Number US05479L1044
Employer ID 46-4478536
SIC Code 2834

Key Executives

Name Position
Francisco D. Salva President, Chief Executive Officer and Director
Travis M. Whitfill M.P.H., Ph.D. Co-Founder, Chief Operating Officer and Director
Norman Staskey Chief Financial Officer, Treasurer and Secretary
Dr. Mark Sampson Chief Scientific Officer

Latest SEC Filings

Date Type Title
Mar 15, 2024 8-K Current Report
Mar 15, 2024 10-K Annual Report
Feb 27, 2024 SC 13G Statement of acquisition of beneficial ownership by individuals
Feb 26, 2024 SC 13G/A [Amend] Statement of acquisition of beneficial ownership by individuals
Feb 26, 2024 SC 13G Statement of acquisition of beneficial ownership by individuals
Feb 15, 2024 424B5 Filing
Feb 14, 2024 8-K Current Report
Feb 13, 2024 EFFECT Notice of Effectiveness
Feb 12, 2024 SC 13G Statement of acquisition of beneficial ownership by individuals
Jan 19, 2024 FWP Free Writing Prospectus